Literature DB >> 9303904

[First melanoma metastases after 10 years and more of remission].

A Peters1, A Lippold, M Hundeiker.   

Abstract

36 (3.5%) of 1015 patients who had ten or more years of follow-up after treatment of invasive malignant melanomas (stage I and II, UICC 1978) in Hornheide 1967-1984 developed late metastases. The mean disease-free interval was 12.5 years. These patients were younger (mean age of 45.8 years) compared to the age of all melanoma patients at the time of primary therapy. The rate of late relapses was 2.8% in women (20/705) and 5% in men (16/310). In melanomas located on the trunk or on the legs in male individuals, the relapse was twice as high as in females. The median tumor thickness in patients with late progression was 1.5 mm; in patients without relapse 1.2 mm. The well known association of tumor thickness with the risk of metastases disappeared after a 10 years disease-free interval. The frequency of metastases (3.5%) did not vary in different thickness classes from 0.76 mm to 3 mm or more. Melanomas with a Breslow thickness < 0.75 mm had a risk of only 1.4%. 23 patients (64%) developed distant, only 13 (36%) regional late metastases as first evidence of recurrent disease. The survival of these patients correlated neither to the duration of previous relapse-free follow up, nor to site of the primary lesion nor to sex. It correlated only to the site of metastases: 83% of all patients with distant late metastases had a remaining life time of 14 months or less, but patients with regional metastases survived more than 7 years in 69% of the cases. We have been unable to define risk factors for late metastases.

Entities:  

Mesh:

Year:  1997        PMID: 9303904     DOI: 10.1007/s001050050588

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  8 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

2.  Malignant melanoma of the skin: long-term follow-up and time to first recurrence.

Authors:  Annika M Hohnheiser; Olaf Gefeller; Jonas Göhl; Gerold Schuler; Werner Hohenberger; Susanne Merkel
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

3.  Late recurrence in melanoma: clinical implications of lost dormancy.

Authors:  Mark B Faries; Shawn Steen; Xing Ye; Myung Sim; Donald L Morton
Journal:  J Am Coll Surg       Date:  2013-05-03       Impact factor: 6.113

Review 4.  Rethinking the biology of metastatic melanoma: a holistic approach.

Authors:  Hendrik Hld Vandyck; Lisa M Hillen; Francesca M Bosisio; Joost van den Oord; Axel Zur Hausen; Véronique Winnepenninckx
Journal:  Cancer Metastasis Rev       Date:  2021-04-19       Impact factor: 9.264

5.  Risk Stratification and Clinical Characteristics of Patients with Late Recurrence of Melanoma (>10 Years).

Authors:  Robin Reschke; Konstantin Dumann; Mirjana Ziemer
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.964

Review 6.  Cancer Metastases: Early Dissemination and Late Recurrences.

Authors:  Sten Friberg; Andreas Nyström
Journal:  Cancer Growth Metastasis       Date:  2015-11-29

7.  Primary and metastatic tumor dormancy as a result of population heterogeneity.

Authors:  Irina Kareva
Journal:  Biol Direct       Date:  2016-08-23       Impact factor: 4.540

8.  Late Metastatic Melanoma after 25 Years: A Case Report and a Brief Literature Review.

Authors:  Elena Pescarini; Gabriela Spanikova; Zacharia Mbaidjol; Eleonora De Antoni; Vincenzo Vindigni; Franco Bassetto
Journal:  Case Rep Surg       Date:  2020-10-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.